Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections

ABSTRACT Introduction: The epidemiology of carbapenem-resistant Enterobacterales (CRE) is increasingly worldwide. Production of carbapenemases is the most common and efficient mechanism of carbapenem resistance, and could theoretically be overcome by optimizing the pharmacokinetic/pharmacodynamic (PK/PD) behavior of meropenem. Areas covered: This article overviews the available literature concerning the potential role that meropenem may still have in the treatment carbapenem-resistant Enterobacteriaceae infections. Clinical studies published in English language until June 2019 were searched on PubMed database. Expert commentary: High-dose continuous infusion meropenem-based combination regimens could still represent a valuable option for treating CRE infections in specific circumstances. Knowledge of the local prevalent mechanisms of carbapenem resistance, of patient clinical severity, of the site of infection, of an accurate minimum inhibitory concentration (MIC) value, coupled with the possibility of carrying-out a real-time therapeutic drug monitoring (TDM)-based PK/PD optimization of drug exposure must all be considered as fundamental for properly pursuing this goal.

[1]  Ronald N. Jones,et al.  The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility? , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. Souli,et al.  Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance , 2019, BMC Infectious Diseases.

[3]  K. Eljaaly,et al.  Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections , 2019, Drugs.

[4]  K. Kazmierczak,et al.  In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). , 2019, International journal of antimicrobial agents.

[5]  K. Mertens,et al.  Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis , 2019, The Lancet. Infectious diseases.

[6]  R. Wunderink,et al.  Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial , 2018, Infectious Diseases and Therapy.

[7]  S. Pongolini,et al.  In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment , 2018, The Journal of antimicrobial chemotherapy.

[8]  L. Leibovici,et al.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[9]  F. Tubau,et al.  Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection , 2018, The Journal of antimicrobial chemotherapy.

[10]  C. Mcnulty,et al.  Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party† , 2018, The Journal of antimicrobial chemotherapy.

[11]  J. Rodríguez-Baño,et al.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae , 2018, Clinical Microbiology Reviews.

[12]  M. Bassetti,et al.  Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. , 2017, International journal of antimicrobial agents.

[13]  M. Dudley,et al.  Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae , 2017, Antimicrobial Agents and Chemotherapy.

[14]  K. Bush,et al.  In vitro activity of plazomicin against &bgr;-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) , 2017, The Journal of antimicrobial chemotherapy.

[15]  D. Marriott,et al.  Too much of a good thing: a retrospective study of &bgr;-lactam concentration–toxicity relationships , 2017, The Journal of antimicrobial chemotherapy.

[16]  M. Bassetti,et al.  Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae , 2017, Antimicrobial Agents and Chemotherapy.

[17]  A. Oliver,et al.  Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. , 2017, The Lancet. Infectious diseases.

[18]  A. Oliver,et al.  Determining &bgr;-lactam exposure threshold to suppress resistance development in Gram-negative bacteria , 2017, The Journal of antimicrobial chemotherapy.

[19]  Robert A. Weinstein,et al.  The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace , 2017, The Journal of infectious diseases.

[20]  M. Bassetti,et al.  Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? , 2017, International journal of antimicrobial agents.

[21]  P. Pelosi,et al.  Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox? , 2017, Virulence.

[22]  B. Kreiswirth,et al.  Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections , 2016, Antimicrobial Agents and Chemotherapy.

[23]  B. Kreiswirth,et al.  Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Bellomo,et al.  Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. , 2016, American journal of respiratory and critical care medicine.

[25]  P. Little,et al.  Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients? , 2016, Minerva anestesiologica.

[26]  Ronald N. Jones,et al.  Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae , 2016, Antimicrobial Agents and Chemotherapy.

[27]  V. Miriagou,et al.  Comparison of Short Versus Prolonged Infusion of Standard Dose of Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae Isolates in Different Patient Groups: A Pharmacokinetic-Pharmacodynamic Approach. , 2016, Journal of pharmaceutical sciences.

[28]  M. Mahoney,et al.  Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. , 2015, International journal of antimicrobial agents.

[29]  R. Humphries,et al.  First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate , 2015, Antimicrobial Agents and Chemotherapy.

[30]  N. Iovine,et al.  Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on the In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae , 2015, Antimicrobial Agents and Chemotherapy.

[31]  M. Bassetti,et al.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. , 2015, The Journal of antimicrobial chemotherapy.

[32]  K. Kazmierczak,et al.  In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013 , 2015, Antimicrobial Agents and Chemotherapy.

[33]  S. Richter,et al.  Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. , 2014, The Journal of antimicrobial chemotherapy.

[34]  S. Blot,et al.  The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. , 2014, Advanced drug delivery reviews.

[35]  L. Leibovici,et al.  Combination therapy for carbapenem-resistant Gram-negative bacteria. , 2014, The Journal of antimicrobial chemotherapy.

[36]  P. Tamma,et al.  Treatment of multidrug-resistant Gram-negative infections in children. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  M. Roberts,et al.  An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. , 2014, The Journal of antimicrobial chemotherapy.

[38]  V. Miriagou,et al.  Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems , 2014, Antimicrobial Agents and Chemotherapy.

[39]  R. Bonomo,et al.  New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World , 2013, Antimicrobial Agents and Chemotherapy.

[40]  Qi Wang,et al.  In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in China , 2013, Antimicrobial Agents and Chemotherapy.

[41]  Hui Wang,et al.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. , 2013, The Lancet. Infectious diseases.

[42]  Jonathan Cohen.  Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. , 2013, The Journal of antimicrobial chemotherapy.

[43]  G. Daikos,et al.  Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective , 2012, Expert review of anti-infective therapy.

[44]  P. Viale,et al.  Dosing Nomograms for Attaining Optimum Concentrations of Meropenem by Continuous Infusion in Critically Ill Patients with Severe Gram-Negative Infections: a Pharmacokinetics/Pharmacodynamics-Based Approach , 2012, Antimicrobial Agents and Chemotherapy.

[45]  M. Bassetti,et al.  Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  R. Pradl,et al.  Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial , 2012, Critical Care.

[47]  P. Lagacé-Wiens,et al.  Adverse reactions to β-lactam antimicrobials , 2012, Expert opinion on drug safety.

[48]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[49]  P. Barie,et al.  Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. , 2011, Surgical infections.

[50]  G. Daikos,et al.  Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[51]  N Woodford,et al.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. , 2011, The Journal of antimicrobial chemotherapy.

[52]  Vincent H Tam,et al.  Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. , 2010, The Journal of antimicrobial chemotherapy.

[53]  P. Viale,et al.  Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock – does the dose matter? , 2009, Critical care.

[54]  H. Derendorf,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline , 2009, Clinical pharmacokinetics.

[55]  T. Slama.  Clinical review: Balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use , 2008, Critical care.

[56]  D. Nicolau.  Pharmacokinetic and pharmacodynamic properties of meropenem. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  D. Nicolau,et al.  Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. , 2007, Diagnostic microbiology and infectious disease.

[58]  P. Viale,et al.  The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  L. Lorente,et al.  Meropenem by Continuous Versus Intermittent Infusion in Ventilator-Associated Pneumonia due to Gram-Negative Bacilli , 2006, The Annals of pharmacotherapy.